Titan Group: Financial Calendar 2026 Regulatory News: Titan S.A. (Euronext Brussels, ATHEX and Euronext Paris, TITC) announces its financial calendar for 2026. 19 March 2026 Publication of the fourth quarter and full year 2025 results 27 March 2026 Publication of the Integrated Annual Report 2025 7 May 2026 Publication of the first quarter 2026 results 7 May 2026 Annual General [...]
OLX Group Reports Record Profitability with 49% Margin and Strong 22% Revenue Growth OLX Group (“OLX”), a global online classifieds leader with nearly 60 million daily listings across seven markets1 and a subsidiary of Prosus, has reported strong financial results for the first six months ended 30 September 2025. Revenue grew 22% (17%2) year-on-year to US$473 million, from US$389 million in 1HY25. Adjusted EBITDA increased 52% (44%) year-on-year [...]
OCP Announces Date of Third Quarter and Nine-Month 2025 Earnings November 19, 2025 OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2025 results on Tuesday, November 25, 2025. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, [...]
Allianz Achieves Record Results and Expects a Full-Year Operating Profit of at Least 17 Billion Euros November 14, 2025 3Q 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113803211/en/ Double-digit growth in operating profit and shareholders’ core net income Total business volume rises 5.21 percent with contributions from all segments Operating profit increases 12.6 percent to 4.4 billion euros, with particular strong contribution from the Property-Casualty segment Shareholders’ core net income [...]
REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2025 November 13, 2025 All economic indicators have substantially improved: Consolidated turnover of €1,819.8 million (1,669.6 as at 30 September 2024) EBITDA of €335.5 million (275.5 as at 30 September 2024) EBIT of €281.0 million (224.2 as at 30 September 2024) Pre-tax profit of €268.1 million (216.0 as at 30 September 2024) Positive Net Financial Position of €423.1 million.
Kolibri Global Energy Announces a 40% Increase in Production and a 15% Increase in Net Revenues for the Third Quarter of 2025 November 12, 2025 All amounts are in U.S. Dollars unless otherwise indicated: THIRD QUARTER 2025 HIGHLIGHTS Average production for the third quarter of 2025 was 4,254 BOEPD, an increase of 40% from the third quarter of 2024 average production of 3,032 BOEPD. The increase was due to production from the wells that were drilled and completed in the [...]
AngloGold Ashanti Q3 and Nine Months Ended 30 September 2025 Earnings Release and Dividend Declaration November 11, 2025 AngloGold Ashanti posts strong Q3 2025 YoY: • Gold production +17% • Total Cash Costs* flat in real terms • Adjusted EBITDA* +109% to $1.6bn • Free Cash Flow* +141% to $920m • Adjusted Net cash* of $450m • Q3 interim Dividend of $460m, or 91cps • Total dividends declared for 9 months YTD of $927m, or 183.5cps
ReNew Announces Results for the Second Quarter for Fiscal Year 2026 (Q2 FY26), Ended September 30, 2025; Reports 84% Net Profit Increase YOY in H1 FY2026 November 10, 2025 ReNew Energy Global Plc (“ReNew” or “the Company”) (Nasdaq: RNW, RNWWW), a leading decarbonization solutions company, today announced its unaudited consolidated IFRS results for the three-month period ended September 30, 2025. Operating Highlights: As of September 30, 2025, the Company’s portfolio consisted of ~18.5 GWs (+1.1 GWh BESS), compared to ~15.6 GWs as of September [...]
Almirall’s 2025 9M Results November 10, 2025 Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology. EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength. Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch. Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a total of €25.4 MM, and Klisyri® growing 22.6% YoY to a total of €20.1 MM, further enhancing Almirall’s position as trusted partner for patients and dermatologists. Continued R&D pipeline progress includes the start of the phase II study of the anti-IL-1RAP mAb, and plan to initiate three additional proof-of-concept studies over the coming 9 to 12 months.